We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Keynote Address to Focus on CRISPR/Cas9 Gene Editing

By LabMedica International staff writers
Posted on 08 Jun 2017
Print article
Image: Gene editing technologies, including CRISPR/Cas9, offer the ability to directly modify or correct the underlying disease-associated changes in our genome (Photo courtesy of CRISPR Therapeutics).
Image: Gene editing technologies, including CRISPR/Cas9, offer the ability to directly modify or correct the underlying disease-associated changes in our genome (Photo courtesy of CRISPR Therapeutics).
The widely used CRISPR/Cas9 genome editing technique is to be the subject of the keynote address of the plenary sessions of the July 30 - August 3, 2017, AACC Annual Meeting & Clinical Lab Expo (San Diego, CA, USA).

The featured speaker will be Dr. Jennifer Doudna, professor of chemistry and molecular and cell biology at the University of California, Berkeley (USA). The title of her presentation is "CRISPR Biology, Technology & Ethics: The Future of Genome Engineering". This presentation will describe how the bacterial CRISPR adaptive immune system continues to inspire development of powerful genome engineering tools, enabling advances in both fundamental biology and applications to the mammalian brain.

CRISPR/Cas9 is regarded as the cutting edge of molecular biology technology. CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. CRISPRs are found in approximately 40% of sequenced bacteria genomes and 90% of sequenced archaea. CRISPRs are often associated with cas genes that code for proteins related to CRISPRs.

Since 2013, the CRISPR/Cas system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides (CRISPRs) that shepherd the Cas9 protein to the target gene on a DNA strand.

The ethics of CRSPR/Cas9 were discussed by a panel of experts, and their remarks were published in the October 2016 issue of the journal Clinical Chemistry. The panelists cautioned that making the methodology cheap and easy enough for poorly funded amateurs could have vast effects by making it harder for anyone to control. They also warned about the potential consequences of off-target effects, including lack of specificity and incomplete targeting, which could have devastating effects on patients.

On the other hand, they suggested that when CRISPR technology becomes completely safe and effective, it could be used to edit somatic cells of people or fetuses and embryos to prevent heritable diseases, even to edit the germline to prevent any future transmission of heritable diseases.

The importance of the future role of CRISPR/Cas9 is underlined by the choice to make this technology the topic of this year's keynote address.

Related Links:
AACC Annual Meeting & Clinical Lab Expo
University of California, Berkeley
New
Gold Supplier
SARS-COV-2 PLUS UK Real Time PCR kit
SARS-COV-2 PLUS UK REALTIME PCR KIT
New
Laboratory Water System
Q-CHE40-SR/Q-CHE80-SR
New
Laboratory Automation System
UniVerse
New
Gold Supplier
BMP Whole Blood Analyzer
GEM Premier ChemSTAT

Print article

Channels

Molecular Diagnostics

view channel
Image: The QuikRead go iFOBT is an immunochemical fecal immunochemical test for detection and quantification of human hemoglobin in feces in case of suspected bleeding from the lower gastrointestinal tract (Photo courtesy of Aidian)

Fecal Immunochemical Tubes Sourced to Analyze Gut Microbiome for CRC

Colorectal cancer (CRC) is a challenging public health problem which successful treatment depends on the stage at diagnosis. Recently, CRC-specific microbiome signatures have been proposed as a marker... Read more

Hematology

view channel
Image: Bone marrow aspirate from a patient with peripheral T-cell lymphoma (Photo courtesy of Peter Maslak, MD)

Mutation Analysis Links Angioimmunoblastic T-Cell Lymphoma to Clonal Hematopoiesis

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoid tumors and encompass peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and... Read more

Industry

view channel
Image: GastroPanel Quick Test (Photo courtesy of Biohit Healthcare)

Biohit’s Innovative GastroPanel Quick Test Receives CE Mark

Biohit Healthcare’s (Helsinki, Finland) GastroPanel Quick Test, the latest innovation in its unique GastroPanel product family, is now CE marked. The GastroPanel Quick Test is intended for diagnosing... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.